4.7 Article

Zinc finger antiviral protein inhibits coxsackievirus B3 virus replication and protects against viral myocarditis

Journal

ANTIVIRAL RESEARCH
Volume 123, Issue -, Pages 50-61

Publisher

ELSEVIER
DOI: 10.1016/j.antiviral.2015.09.001

Keywords

Zinc finger antiviral protein; Coxsackievirus B3; Viral myocarditis

Funding

  1. China NSFC Grant [31470869, 31072973, 31400769]
  2. Major State Basic Research Development Program of China [2013CB530501]
  3. Natural Science foundation of Jiangsu Province Higher education [14KJA310005, BK20140371]
  4. Jiangsu Provincial Innovative Research Team - priority Academic Program Development of Jiangsu Higher Education Institutions
  5. Program for Changjiang Scholars and Innovative Research Team in University [PCSIRTIRT1075]

Ask authors/readers for more resources

The host Zinc finger antiviral protein (ZAP) has been reported exhibiting antiviral activity against positive-stranded RNA viruses (Togaviridae), negative-stranded RNA viruses (Filoviridae) and retroviruses (Retroviridae). However, whether ZAP restricts the infection of enterovirus and the development of enterovirus mediated disease remains unknown. Here, we reported the antiviral properties of ZAP against coxsackievirus B3 (CVB3), a single-stranded RNA virus of the Enterovints genus within the Picornaviridae as a major causative agent of viral myocarditis (VMC). We found that the expression of ZAP was significantly induced after CVB3 infection in heart tissues of VMC mice. ZAP potently inhibited CVB3 replication in cells after infection, while overexpression of ZAP in mice significantly increased the resistance to CVB3 replication and viral myocarditis by significantly reducing cardiac inflammatory cytokine production. The ZAP-responsive elements (ZREs) were mapped to the 3'UTR and 5'UTR of viral RNA. Taken together, ZAP confers resistance to CVB3 infection via directly targeting viral RNA and protects mice from acute myocarditis by suppressing viral replication and cardiac inflammatory cytokine production. Our finding further expands ZAP's range of viral targets, and suggests ZAP as a potential therapeutic target for viral myocarditis caused by CVB3. (C) 2015 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available